Systematic Review and Patient-Level Meta-analysis of the Streamliner Multilayer Flow Modulator in the Management of Complex Thoracoabdominal Aortic Pathology

Conclusion:
The SMFM can be safely utilized in some patients with complex thoracoabdominal pathologies provided operators adhere to the IFU. The SMFM is a novel technology with no long-term published data on its sustained effectiveness and a lack of comparative studies. Randomized clinical trials, registries, and continued assessment are essential before this flow-modulating technology can be widely disseminated.

Source: Journal of Endovascular Therapy - May 10, 2016 Category: Surgery Authors: Hynes, N., Sultan, S., Elhelali, A., Diethrich, E. B., Kavanagh, E. P., Sultan, M., Stefanov, F., Delassus, P., Morris, L. Tags: Thoracoabdominal Aortic Interventions Source Type: research